The exact function of differentiation antigen mesothelin (MSLN) is unclear, but scientists know it is typically expressed in mesothelial cells in the pleural, pericardium, and peritoneum. Mesothelin is highly expressed in several human cancers, including mesotheliomas, pancreatic adenocarcinomas, and approximately 70% of ovarian cancers and 50% of lung adenocarcinomas. Preclinical and clinical studies have shown that overexpression of mesothelin can promote tumor cell proliferation and invasion. While these factors indicate that mesothelin could be a promising target for cancer therapy, antibody-based drugs targeting mesothelin have either shown limited therapeutic effect or caused severe adverse events.